The risk of keratitis previously identified with panitumumab is now considered a class effect for all epidermal growth factor receptor (EGFR) inhibitors

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1405, 2012-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Acneiform folliculitis associated with epidermal growth factor receptor (EGFR) inhibitors requires sympathetic treatment of mild, as well as severe, symptoms

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 25, Iss. 6, 2009-06 ,pp. : 24-26

Adis International

Access to resources Recommend Favorite

Docking and Molecular Dynamics Study on the Inhibitory Activity of Novel Inhibitors on Epidermal Growth Factor Receptor (EGFR)

By  

Medicinal Chemistry, Vol. 7, Iss. 1, 2011-01 ,pp. : 24-31

Bentham Science Publishers

Access to resources Recommend Favorite

QSAR and Molecular Docking Studies on a Series of Cinnamic Acid Analogues as Epidermal Growth Factor Receptor (EGFR) Inhibitors

By  

Letters in Drug Design & Discovery, Vol. 14, Iss. 1, 2017-01 ,pp. : 83-95

Bentham Science Publishers

Access to resources Recommend Favorite

Putting the Brakes on Cancer: Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

By  

Pharmaceutical Innovation, Vol. 12, Iss. 1, 2002-12 ,pp. : 12-15

Adis International

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer

By Dancey Janet E.  

Drugs, Vol. 67, Iss. 8, 2007-01 ,pp. : 1125-1138

Adis International

Access to resources Recommend Favorite